COVID-19 diagnostic study of choice: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
The diagnostic criteria for suspected and confirmed cases of | The diagnostic criteria for suspected and confirmed cases of [[coronavirus]] disease 2019 ([[COVID-19]]) are tabulated in the section below. | ||
==Diagnostic Study of Choice== | ==Diagnostic Study of Choice== | ||
=== Diagnostic Criteria === | === Diagnostic Criteria === | ||
The diagnostic criteria for suspected and confirmed cases of | The diagnostic criteria for suspected and confirmed cases of [[coronavirus]] disease 2019 ([[COVID-19]]) is tabulated below:<ref name="ChenZhou2020">{{cite journal|last1=Chen|first1=Nanshan|last2=Zhou|first2=Min|last3=Dong|first3=Xuan|last4=Qu|first4=Jieming|last5=Gong|first5=Fengyun|last6=Han|first6=Yang|last7=Qiu|first7=Yang|last8=Wang|first8=Jingli|last9=Liu|first9=Ying|last10=Wei|first10=Yuan|last11=Xia|first11=Jia'an|last12=Yu|first12=Ting|last13=Zhang|first13=Xinxin|last14=Zhang|first14=Li|title=Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study|journal=The Lancet|volume=395|issue=10223|year=2020|pages=507–513|issn=01406736|doi=10.1016/S0140-6736(20)30211-7}}</ref><ref>{{Cite web|url=http://www.nhc.gov.cn/xcs/zhengcwj/202002/de2d62a5711c41ef9b2c4b6f4d1f2136.shtml|title=C.N.H. Commission | ||
Notice on prevention and control of pneumonia in children and pregnant women with new coronavirus infection | Notice on prevention and control of pneumonia in children and pregnant women with new coronavirus infection | ||
China National Health Commission, Beijing (2020) | China National Health Commission, Beijing (2020) | ||
| Line 23: | Line 23: | ||
|- | |- | ||
!Suspected Case | !Suspected Case | ||
|Anyone with a history of epidemiology and any two of the clinical manifestations or anyone without epidemiological history and three of the clinical manifestations is considered to be a suspected case: | |Anyone with a history of [[epidemiology]] and any two of the clinical manifestations or anyone without [[Epidemiology|epidemiological]] history and three of the clinical manifestations is considered to be a suspected case: | ||
'''1) Epidemiological history:''' | '''1) Epidemiological history:''' | ||
* Within 14 days before the disease onset, there is a travel history or living history in Wuhan or other areas with local cases | * Within 14 days before the disease onset, there is a travel history or living history in Wuhan or other areas with local cases | ||
* Within 14 days before the disease onset, there is contact with patients who had a fever or respiratory symptoms from Wuhan or other areas with local cases | * Within 14 days before the disease onset, there is contact with patients who had a fever or [[respiratory]] symptoms from Wuhan or other areas with local cases | ||
* | * Clustering of patients or contact with patients infected with the [[SARS-CoV-2]] | ||
'''2) Clinical manifestations:''' | '''2) Clinical manifestations:''' | ||
* Fever and/or respiratory symptoms | *[[Fever]] and/or respiratory symptoms | ||
*With the above-mentioned imaging characteristics of pneumonia | *With the above-mentioned imaging characteristics of [[pneumonia]] | ||
*The total number of leukocytes in the early stage of the disease is normal or decreased, or the lymphocyte count is decreased | *The total number of [[leukocytes]] in the early stage of the disease is normal or decreased, or the lymphocyte count is decreased | ||
|- | |- | ||
!Confirmed Case | !Confirmed Case | ||
|Any suspected case with one of the following pathogenic features is reclassified as a confirmed case: | |Any suspected case with one of the following pathogenic features is reclassified as a confirmed case: | ||
* Positive results of SARS-CoV-2 nucleic acids by real-time reverse-transcriptase polymerase-chain-reaction (RT-PCR) of respiratory or blood specimens | * Positive results of [[SARS-CoV-2]] [[Nucleic acid|nucleic acids]] by real-time reverse-transcriptase polymerase-chain-reaction ([[Reverse transcription polymerase chain reaction|RT]]-[[Polymerase chain reaction|PCR]]) of respiratory or blood specimens | ||
*DNA highly homologous to SARS-CoV-2 by genetic sequencing of viral genes in respiratory or blood specimens<br /> | *[[DNA]] highly [[Homology (biology)|homologous]] to [[SARS-CoV-2]] by genetic sequencing of viral [[genes]] in respiratory or blood specimens<br /> | ||
|} | |} | ||
| Line 47: | Line 47: | ||
== Ongoing diagnostic Trials == | == Ongoing diagnostic Trials == | ||
* A researcher at Israel’s Ben-Gurion University of the Negev (BGU) has developed a test that identifies those carrying the COVID-19 virus in less than a minute. And it is both affordable and works with greater than 90% accuracy to boot<ref>{{Cite web|url=https://www.bioworld.com/articles/435285-Israels-ben-Gurion-university-develops-one-minute-coronavirus-test.html|title=|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref> | * A researcher at Israel’s Ben-Gurion University of the Negev (BGU) has developed a test that identifies those carrying the COVID-19 virus in less than a minute. And it is both affordable and works with greater than 90% accuracy to boot<ref>{{Cite web|url=https://www.bioworld.com/articles/435285-Israels-ben-Gurion-university-develops-one-minute-coronavirus-test.html|title=|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref> | ||
====Antibody response==== | ====Antibody response==== | ||
* Most recovering from #COVID19 do not have high levels of neutralizing antibodies BUT antibodies to the receptor binding domain (RBD) of the spike protein with potent antiviral activity were found in all individuals tested & may be tx target<ref name="RobbianiGaebler2020">{{cite journal|last1=Robbiani|first1=Davide F.|last2=Gaebler|first2=Christian|last3=Muecksch|first3=Frauke|last4=Lorenzi|first4=Julio C. C.|last5=Wang|first5=Zijun|last6=Cho|first6=Alice|last7=Agudelo|first7=Marianna|last8=Barnes|first8=Christopher O.|last9=Gazumyan|first9=Anna|last10=Finkin|first10=Shlomo|last11=Hägglöf|first11=Thomas|last12=Oliveira|first12=Thiago Y.|last13=Viant|first13=Charlotte|last14=Hurley|first14=Arlene|last15=Hoffmann|first15=Hans-Heinrich|last16=Millard|first16=Katrina G.|last17=Kost|first17=Rhonda G.|last18=Cipolla|first18=Melissa|last19=Gordon|first19=Kristie|last20=Bianchini|first20=Filippo|last21=Chen|first21=Spencer T.|last22=Ramos|first22=Victor|last23=Patel|first23=Roshni|last24=Dizon|first24=Juan|last25=Shimeliovich|first25=Irina|last26=Mendoza|first26=Pilar|last27=Hartweger|first27=Harald|last28=Nogueira|first28=Lilian|last29=Pack|first29=Maggi|last30=Horowitz|first30=Jill|last31=Schmidt|first31=Fabian|last32=Weisblum|first32=Yiska|last33=Michailidis|first33=Eleftherios|last34=Ashbrook|first34=Alison W.|last35=Waltari|first35=Eric|last36=Pak|first36=John E.|last37=Huey-Tubman|first37=Kathryn E.|last38=Koranda|first38=Nicholas|last39=Hoffman|first39=Pauline R.|last40=West|first40=Anthony P.|last41=Rice|first41=Charles M.|last42=Hatziioannou|first42=Theodora|last43=Bjorkman|first43=Pamela J.|last44=Bieniasz|first44=Paul D.|last45=Caskey|first45=Marina|last46=Nussenzweig|first46=Michel C.|title=Convergent antibody responses to SARS-CoV-2 in convalescent individuals|journal=Nature|year=2020|issn=0028-0836|doi=10.1038/s41586-020-2456-9}}</ref> | * Most recovering from #[[COVID-19|COVID19]] do not have high levels of neutralizing [[antibodies]] BUT [[antibodies]] to the receptor binding domain (RBD) of the spike protein with potent antiviral activity were found in all individuals tested & may be tx target<ref name="RobbianiGaebler2020">{{cite journal|last1=Robbiani|first1=Davide F.|last2=Gaebler|first2=Christian|last3=Muecksch|first3=Frauke|last4=Lorenzi|first4=Julio C. C.|last5=Wang|first5=Zijun|last6=Cho|first6=Alice|last7=Agudelo|first7=Marianna|last8=Barnes|first8=Christopher O.|last9=Gazumyan|first9=Anna|last10=Finkin|first10=Shlomo|last11=Hägglöf|first11=Thomas|last12=Oliveira|first12=Thiago Y.|last13=Viant|first13=Charlotte|last14=Hurley|first14=Arlene|last15=Hoffmann|first15=Hans-Heinrich|last16=Millard|first16=Katrina G.|last17=Kost|first17=Rhonda G.|last18=Cipolla|first18=Melissa|last19=Gordon|first19=Kristie|last20=Bianchini|first20=Filippo|last21=Chen|first21=Spencer T.|last22=Ramos|first22=Victor|last23=Patel|first23=Roshni|last24=Dizon|first24=Juan|last25=Shimeliovich|first25=Irina|last26=Mendoza|first26=Pilar|last27=Hartweger|first27=Harald|last28=Nogueira|first28=Lilian|last29=Pack|first29=Maggi|last30=Horowitz|first30=Jill|last31=Schmidt|first31=Fabian|last32=Weisblum|first32=Yiska|last33=Michailidis|first33=Eleftherios|last34=Ashbrook|first34=Alison W.|last35=Waltari|first35=Eric|last36=Pak|first36=John E.|last37=Huey-Tubman|first37=Kathryn E.|last38=Koranda|first38=Nicholas|last39=Hoffman|first39=Pauline R.|last40=West|first40=Anthony P.|last41=Rice|first41=Charles M.|last42=Hatziioannou|first42=Theodora|last43=Bjorkman|first43=Pamela J.|last44=Bieniasz|first44=Paul D.|last45=Caskey|first45=Marina|last46=Nussenzweig|first46=Michel C.|title=Convergent antibody responses to SARS-CoV-2 in convalescent individuals|journal=Nature|year=2020|issn=0028-0836|doi=10.1038/s41586-020-2456-9}}</ref> | ||
*8 weeks after hospital discharge, 40% of asymptomatic patients have no antibodies, and 12.9% of those who were symptomatic had no #COVID19 antibodies<ref name="LongTang2020">{{cite journal|last1=Long|first1=Quan-Xin|last2=Tang|first2=Xiao-Jun|last3=Shi|first3=Qiu-Lin|last4=Li|first4=Qin|last5=Deng|first5=Hai-Jun|last6=Yuan|first6=Jun|last7=Hu|first7=Jie-Li|last8=Xu|first8=Wei|last9=Zhang|first9=Yong|last10=Lv|first10=Fa-Jin|last11=Su|first11=Kun|last12=Zhang|first12=Fan|last13=Gong|first13=Jiang|last14=Wu|first14=Bo|last15=Liu|first15=Xia-Mao|last16=Li|first16=Jin-Jing|last17=Qiu|first17=Jing-Fu|last18=Chen|first18=Juan|last19=Huang|first19=Ai-Long|title=Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections|journal=Nature Medicine|year=2020|issn=1078-8956|doi=10.1038/s41591-020-0965-6}}</ref> | *8 weeks after hospital discharge, 40% of asymptomatic patients have no antibodies, and 12.9% of those who were symptomatic had no #COVID19 antibodies<ref name="LongTang2020">{{cite journal|last1=Long|first1=Quan-Xin|last2=Tang|first2=Xiao-Jun|last3=Shi|first3=Qiu-Lin|last4=Li|first4=Qin|last5=Deng|first5=Hai-Jun|last6=Yuan|first6=Jun|last7=Hu|first7=Jie-Li|last8=Xu|first8=Wei|last9=Zhang|first9=Yong|last10=Lv|first10=Fa-Jin|last11=Su|first11=Kun|last12=Zhang|first12=Fan|last13=Gong|first13=Jiang|last14=Wu|first14=Bo|last15=Liu|first15=Xia-Mao|last16=Li|first16=Jin-Jing|last17=Qiu|first17=Jing-Fu|last18=Chen|first18=Juan|last19=Huang|first19=Ai-Long|title=Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections|journal=Nature Medicine|year=2020|issn=1078-8956|doi=10.1038/s41591-020-0965-6}}</ref> | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 20:46, 28 June 2020
For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here
|
COVID-19 Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
COVID-19 diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of COVID-19 diagnostic study of choice |
|
Risk calculators and risk factors for COVID-19 diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]
Overview
The diagnostic criteria for suspected and confirmed cases of coronavirus disease 2019 (COVID-19) are tabulated in the section below.
Diagnostic Study of Choice
Diagnostic Criteria
The diagnostic criteria for suspected and confirmed cases of coronavirus disease 2019 (COVID-19) is tabulated below:[1][2][3][4][5][6]
| Case | Diagnostic Criteria |
|---|---|
| Suspected Case | Anyone with a history of epidemiology and any two of the clinical manifestations or anyone without epidemiological history and three of the clinical manifestations is considered to be a suspected case:
1) Epidemiological history:
|
| Confirmed Case | Any suspected case with one of the following pathogenic features is reclassified as a confirmed case:
|
Ongoing diagnostic Trials
- A researcher at Israel’s Ben-Gurion University of the Negev (BGU) has developed a test that identifies those carrying the COVID-19 virus in less than a minute. And it is both affordable and works with greater than 90% accuracy to boot[7]
Antibody response
- Most recovering from #COVID19 do not have high levels of neutralizing antibodies BUT antibodies to the receptor binding domain (RBD) of the spike protein with potent antiviral activity were found in all individuals tested & may be tx target[8]
- 8 weeks after hospital discharge, 40% of asymptomatic patients have no antibodies, and 12.9% of those who were symptomatic had no #COVID19 antibodies[9]
References
- ↑ Chen, Nanshan; Zhou, Min; Dong, Xuan; Qu, Jieming; Gong, Fengyun; Han, Yang; Qiu, Yang; Wang, Jingli; Liu, Ying; Wei, Yuan; Xia, Jia'an; Yu, Ting; Zhang, Xinxin; Zhang, Li (2020). "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study". The Lancet. 395 (10223): 507–513. doi:10.1016/S0140-6736(20)30211-7. ISSN 0140-6736.
- ↑ "C.N.H. Commission Notice on prevention and control of pneumonia in children and pregnant women with new coronavirus infection China National Health Commission, Beijing (2020) (in Chinese)". line feed character in
|title=at position 18 (help) - ↑ "Technology, M.e.g.o.T.h.a.t.T.M.C.o.H.U.o.S.a. A rapid guideline for the diagnosis and treatment of pneumonia with new coronavirus infection (Third edition)".
- ↑ "Union Hospital T.M.C., Huazhong University of Science and Technology., Wuhan union hospital manage the 2019 new coronavirus infection strategies and instructions (in Chinese)". line feed character in
|title=at position 15 (help) - ↑ "[Diagnosis and clinical management of 2019 novel coronavirus infection: an operational recommendation of Peking Union Medical College Hospital (V2.0)]". Zhonghua Nei Ke Za Zhi (in Chinese). 59 (3): 186–188. February 2020. doi:10.3760/cma.j.issn.0578-1426.2020.03.003. PMID 32023681 Check
|pmid=value (help). - ↑ "Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected".
- ↑ https://www.bioworld.com/articles/435285-Israels-ben-Gurion-university-develops-one-minute-coronavirus-test.html. Missing or empty
|title=(help) - ↑ Robbiani, Davide F.; Gaebler, Christian; Muecksch, Frauke; Lorenzi, Julio C. C.; Wang, Zijun; Cho, Alice; Agudelo, Marianna; Barnes, Christopher O.; Gazumyan, Anna; Finkin, Shlomo; Hägglöf, Thomas; Oliveira, Thiago Y.; Viant, Charlotte; Hurley, Arlene; Hoffmann, Hans-Heinrich; Millard, Katrina G.; Kost, Rhonda G.; Cipolla, Melissa; Gordon, Kristie; Bianchini, Filippo; Chen, Spencer T.; Ramos, Victor; Patel, Roshni; Dizon, Juan; Shimeliovich, Irina; Mendoza, Pilar; Hartweger, Harald; Nogueira, Lilian; Pack, Maggi; Horowitz, Jill; Schmidt, Fabian; Weisblum, Yiska; Michailidis, Eleftherios; Ashbrook, Alison W.; Waltari, Eric; Pak, John E.; Huey-Tubman, Kathryn E.; Koranda, Nicholas; Hoffman, Pauline R.; West, Anthony P.; Rice, Charles M.; Hatziioannou, Theodora; Bjorkman, Pamela J.; Bieniasz, Paul D.; Caskey, Marina; Nussenzweig, Michel C. (2020). "Convergent antibody responses to SARS-CoV-2 in convalescent individuals". Nature. doi:10.1038/s41586-020-2456-9. ISSN 0028-0836.
- ↑ Long, Quan-Xin; Tang, Xiao-Jun; Shi, Qiu-Lin; Li, Qin; Deng, Hai-Jun; Yuan, Jun; Hu, Jie-Li; Xu, Wei; Zhang, Yong; Lv, Fa-Jin; Su, Kun; Zhang, Fan; Gong, Jiang; Wu, Bo; Liu, Xia-Mao; Li, Jin-Jing; Qiu, Jing-Fu; Chen, Juan; Huang, Ai-Long (2020). "Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections". Nature Medicine. doi:10.1038/s41591-020-0965-6. ISSN 1078-8956.